ストックスクリーナーアプリを入手
8.70
0.11%
-0.01
アフターアワーズ：
8.70
前日終値:
$8.71
開ける：
$8.775
24時間の取引高:
37,197
Relative Volume:
0.72
時価総額：
$184.58M
収益：
-
当期純損益:
$-28.50M
株価収益率:
-4.7992
EPS:
-1.8128
ネットキャッシュフロー:
$-25.87M
1週間 パフォーマンス:
-6.65%
1か月 パフォーマンス:
-7.45%
6か月 パフォーマンス:
+22.19%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$8.535
$8.86
1週間の範囲:
$8.36
$9.47
52週間の値動き範囲:
$5.44
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Compare MSLE vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
8.70 | 184.58M | 0 | -28.50M | -25.87M | -1.8128 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-06 | 開始されました | Leerink Partners | Outperform |
| 2026-03-11 | 開始されました | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc (MSLE) 最新ニュース
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - Investing News Network
Satellos Receives FDA Clearance For FSHD Investigational New Drug Application - marketscreener.com
Satellos Bioscience Inc. - Baystreet.ca
Stocks in play: Satellos Bioscience Inc. - ca.finance.yahoo.com
Satellos Receives FDA Clearance to Study Forazapadin in FSHD - Yahoo Finance
Satellos stock jumps after FDA clears FSHD trial for forazapadin - Yahoo Finance
Satellos stock jumps after FDA clears FSHD trial for forazapadin By Investing.com - Investing.com Australia
Satellos receives FDA clearance for FSHD drug trial - Investing.com
Satellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding - TipRanks
Satellos Bioscience Inc. (MSLE) Stock Price, News, Quote & History - Yahoo! Finance Canada
FDA clears a Satellos (MSLE) drug study for a disease affecting an estimated 800,000 people worldwide. - Stock Titan
Satellos receives FDA clearance for FSHD drug trial By Investing.com - Investing.com Canada
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - Caledon Enterprise
Satellos Bioscience Inc.(NasdaqGM: MSLE) added to S&P Global BMI Index - marketscreener.com
Satellos at H.C. Wainwright conference: DMD drug aims wider - Investing.com
Satellos Bioscience to Showcase Forazapadin Program at World Muscle Society Congress - TipRanks
Satellos Bioscience Announces Four Poster Presentations at the 2026 World Muscle Society Congress - Quiver Quantitative
Cash runway through 2027 backs Satellos (MSLE) muscle disease trials - Stock Titan
WHY Draganfly (CN:DPRO), Eco (Atlantic) Oil & Gas (TSXV:EOG), Mayfair Gold (TSXV:MFG), Satellos Bioscience (TSX:MSCL) and Foraco International SA (TSX:FAR) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca
Satellos Bioscience Stock Faces Downside Pressure as Clinical Expectations Rise: Is Correction Risk Building? - kalkine.ca
Satellos Bioscience Stock Drops 5.24%: Is TSX:MSCL Facing a Sentiment-Driven Correction Ahead of Key Clinical Catalysts? - kalkine.ca
What's Going On With Satellos Bioscience Inc. Stock Friday? - Wealth Awesome
Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
Satellos Bioscience (TSX:MSCL) Gains Momentum as Clinical Progress and Regenerative Medicine Potential Drive Investor Optimism - kalkine.ca
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 - Investing News Network
Satellos at Cantor healthcare conference: pipeline nears key data - Investing.com
Satellos at Cantor healthcare conference: pipeline nears key data By Investing.com - Investing.com UK
MSCL: Phase II trials of forazapadin show early promise in muscle regeneration, with pivotal data expected soon - TradingView
Satellos Bioscience is facing clinical execution risks—can it regain investor confidence and turn sentiment around? - kalkine.ca
Satellos assigns INN forazapadin to DMD drug candidate By Investing.com - Investing.com Canada
Satellos assigns INN forazapadin to DMD drug candidate - Investing.com
Satellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance - TipRanks
New muscle disease pill from Satellos Bioscience (MSLE) nears key Duchenne trial readout - Stock Titan
A muscle disease treatment candidate gets a new global name: forazapadin - Stock Titan
Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Did Satellos Bioscience (TSX:MSCL) Surge 7.43% on 31 August 2026? - kalkine.ca
Satellos Bioscience to Showcase DMD Drug Program at September Investor Conferences - TipRanks
Satellos to Participate in Upcoming Investor Conferences - The Manila Times
Satellos cash runway through 2027, Phase 2 DMD | MSLE SEC FilingForm 6-K - Stock Titan
Satellos Bioscience (TSX:MSCL) Rises 7.43% as Duchenne Clinical Progress and Upcoming Data Catalysts Lift Investor Optimism - kalkine.ca
Satellos Bioscience Stock Falls 7.42% as Clinical-Stage Risk and Development Uncertainty Pressure Sentiment - kalkine.ca
Satellos Bioscience Inc. (TSX:MSCL) Falls 7.42% as Biotech Volatility and Clinical Development Risks Pressure Investor Confidence - kalkine.ca
LifeSci Capital Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Satellos Bioscience (MSLE) Slides Nearly 10% in High-Volume Biotech SelloffCalendar Spread Trade - vinanet.vn
Empery Asset Management LP Sells 123,000 Shares of Satellos Bioscience Inc. $MSLE - marketbeat.com
Could Satellos Bioscience (TSX:MSCL) Redefine Muscle Regeneration? - Kalkine Media
LifeSci Capital Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $22 - Moomoo
LifeSci Capital Initiates Satellos Bioscience at Outperform - Yahoo Finance
Satellos Bioscience Stock Under Pressure as Biotech Volatility Raises Correction Risk - kalkine.ca
Satellos (MSLE) Stock: Ends Higher by 0.59% at $10.15 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries in the Latest ReadingMonthly Profile - vinanet.vn
DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances - Streetwise Reports
Satellos Bioscience Inc (MSLE) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):